Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.
about
Eribulin in Cancer TreatmentInitial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing programEribulin mesylate in the treatment of metastatic breast cancerPharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicinPopulation pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.Potential clinical applications of halichondrins in breast cancer and other neoplasms.Eribulin -- a review of preclinical and clinical studies.Eribulin in advanced liposarcoma and leiomyosarcoma.Eribulin in non-small cell lung cancer: challenges and potential strategies.Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors.Eribulin mesylate in breast cancer.
P2860
Q26799328-9215FB96-29FC-4321-92FC-4F9B4B765D0AQ34683835-0B1C2528-537B-4503-947C-DCF9213EF149Q35699382-4B1D92D2-DFAB-4EE6-8C30-CF608868DB2DQ36629243-159A6F03-71BE-4A44-A151-4855899C1522Q37161899-73CD018C-17AC-484C-AF13-1A28EBCDAE0CQ37356164-339D62D3-18DF-4CF7-B2BF-61FA5AEE2896Q37637936-226C3036-4840-4F68-81A9-4283A9527550Q38722807-F1F92FB5-DE9A-4488-A99F-92878A6FBF69Q39120142-84EC7771-EAB9-4B83-B1B5-94E0C4BBE123Q42715686-39995B5C-0B47-46E4-BE4B-A7748DB7211EQ47111016-3FACA690-8896-457F-9834-F4725B50529BQ51091552-952E2552-6817-41E4-98D7-FF4898C5142EQ51301390-53F0F7C9-EA02-480F-AB26-BBC5D861C979Q54694130-F0061F78-00C0-4E49-BA62-55C2B2B3A676
P2860
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Eribulin mesylate pharmacokine ...... ng repeated oral ketoconazole.
@en
Eribulin mesylate pharmacokine ...... ng repeated oral ketoconazole.
@nl
type
label
Eribulin mesylate pharmacokine ...... ng repeated oral ketoconazole.
@en
Eribulin mesylate pharmacokine ...... ng repeated oral ketoconazole.
@nl
prefLabel
Eribulin mesylate pharmacokine ...... ng repeated oral ketoconazole.
@en
Eribulin mesylate pharmacokine ...... ng repeated oral ketoconazole.
@nl
P2093
P2860
P1476
Eribulin mesylate pharmacokine ...... ng repeated oral ketoconazole.
@en
P2093
J H Beijnen
J H M Schellens
L A Devriese
L Reyderman
M Mergui-Roelvink
S Marchetti
P2860
P2888
P304
P356
10.1007/S10637-012-9829-3
P577
2012-05-05T00:00:00Z
P6179
1019090133